• Something wrong with this record ?

Histologic diversity in chromophobe renal cell carcinoma does not impact survival outcome: A comparative international multi-institutional study

J. Kolar, AF. Llaurado, M. Ulamec, F. Skenderi, D. Perez-Montiel, I. Alvarado-Cabrero, S. Bulimbasic, M. Sperga, M. Tretiakova, AO. Osunkoya, J. Rogala, E. Comperat, V. Gal, A. Dunatov, K. Pivovarcikova, K. Michalova, AB. Vesela, M. Slisarenko,...

. 2022 ; 60 (-) : 151978. [pub] 20220520

Language English Country United States

Document type Comparative Study, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc22033219

Predicting the clinical behavior and trajectory of chromophobe renal cell carcinoma (ChRCC) by histologic features has so far proven to be challenging. It is known that ChRCC represents a heterogeneous group of neoplasms demonstrating variable, yet distinctive morphologic and genetic profiles. In this international multi-institutional study, we aimed to assess the impact of histologic diversity in ChRCC (classic/eosinophilic versus rare subtypes) on survival outcome. This is an international multi-institutional matched case-control study including 14 institutions, examining the impact of histologic subtypes of ChRCC on survival outcome. The study group (cases) included 89 rare subtypes of ChRCC. The control group consisted of 70 cases of ChRCC including classic and eosinophilic features, age- and tumor size-matched. Most of the rare subtypes were adenomatoid cystic/pigmented ChRCC (66/89, 74.2%), followed by multicystic ChRCC (10/89, 11.2%), and papillary ChRCC (9/89, 10.1%). In the control group, there were 62 (88.6%) classic and 8 (11.4%) eosinophilic ChRCC. There were no statistically significant differences between the study and control groups for age at diagnosis, gender distribution, tumor size, presence of tumor necrosis, presence of sarcomatoid differentiation, and adverse outcomes. No statistically significant differences were found in clinical outcome between the rare subtypes and classic/eosinophilic groups by tumor size, necrosis, and sarcomatoid differentiation. Further, no statistically significant differences were found in clinical outcome between the two groups, stratified by tumor size, necrosis, and sarcomatoid differentiation. Our findings corroborated previous studies that both sarcomatoid differentiation and tumor necrosis were significantly associated with poor clinical outcome in classic/eosinophilic ChRCC, and this was proven to be true for ChRCC with rare histologic subtypes as well. This study suggests that rare morphologic patterns in ChRCC without other aggressive features play no role in determining the clinical behavior of the tumor.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033219
003      
CZ-PrNML
005      
20230131151141.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.anndiagpath.2022.151978 $2 doi
035    __
$a (PubMed)35609473
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kolar, Jiri $u Department of Urology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
245    10
$a Histologic diversity in chromophobe renal cell carcinoma does not impact survival outcome: A comparative international multi-institutional study / $c J. Kolar, AF. Llaurado, M. Ulamec, F. Skenderi, D. Perez-Montiel, I. Alvarado-Cabrero, S. Bulimbasic, M. Sperga, M. Tretiakova, AO. Osunkoya, J. Rogala, E. Comperat, V. Gal, A. Dunatov, K. Pivovarcikova, K. Michalova, AB. Vesela, M. Slisarenko, AP. Strakova, T. Pitra, M. Hora, M. Michal, R. Alaghehbandan, O. Hes
520    9_
$a Predicting the clinical behavior and trajectory of chromophobe renal cell carcinoma (ChRCC) by histologic features has so far proven to be challenging. It is known that ChRCC represents a heterogeneous group of neoplasms demonstrating variable, yet distinctive morphologic and genetic profiles. In this international multi-institutional study, we aimed to assess the impact of histologic diversity in ChRCC (classic/eosinophilic versus rare subtypes) on survival outcome. This is an international multi-institutional matched case-control study including 14 institutions, examining the impact of histologic subtypes of ChRCC on survival outcome. The study group (cases) included 89 rare subtypes of ChRCC. The control group consisted of 70 cases of ChRCC including classic and eosinophilic features, age- and tumor size-matched. Most of the rare subtypes were adenomatoid cystic/pigmented ChRCC (66/89, 74.2%), followed by multicystic ChRCC (10/89, 11.2%), and papillary ChRCC (9/89, 10.1%). In the control group, there were 62 (88.6%) classic and 8 (11.4%) eosinophilic ChRCC. There were no statistically significant differences between the study and control groups for age at diagnosis, gender distribution, tumor size, presence of tumor necrosis, presence of sarcomatoid differentiation, and adverse outcomes. No statistically significant differences were found in clinical outcome between the rare subtypes and classic/eosinophilic groups by tumor size, necrosis, and sarcomatoid differentiation. Further, no statistically significant differences were found in clinical outcome between the two groups, stratified by tumor size, necrosis, and sarcomatoid differentiation. Our findings corroborated previous studies that both sarcomatoid differentiation and tumor necrosis were significantly associated with poor clinical outcome in classic/eosinophilic ChRCC, and this was proven to be true for ChRCC with rare histologic subtypes as well. This study suggests that rare morphologic patterns in ChRCC without other aggressive features play no role in determining the clinical behavior of the tumor.
650    _2
$a lidé $7 D006801
650    _2
$a nádorové biomarkery $7 D014408
650    12
$a karcinom z renálních buněk $x patologie $7 D002292
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a nádory ledvin $x patologie $7 D007680
650    _2
$a nekróza $7 D009336
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Llaurado, Andrea Feu $u Department of Pathology, Bellvitge Hospital, Barcelona, Spain
700    1_
$a Ulamec, Monika $u Department of Pathology, Sestre milosrdnice University Hospital Center, Department of Pathology and Scientific Centre of Excellence for Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb, Croatia
700    1_
$a Skenderi, Faruk $u Department of Pathology, University of Sarajevo, Faculty of Health Sciences, Sarajevo, Bosnia and Herzegovina
700    1_
$a Perez-Montiel, Delia $u Department of Pathology, Institute Nacional de Cancerologia, Mexico City, Mexico
700    1_
$a Alvarado-Cabrero, Isabel $u Department of Pathology, Centro Medico, Mexico City, Mexico
700    1_
$a Bulimbasic, Stela $u Department of Pathology, University Hospital Zagreb, Croatia
700    1_
$a Sperga, Maris $u Department of Pathology, Stradin's University, Riga, Latvia
700    1_
$a Tretiakova, Maria $u Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
700    1_
$a Osunkoya, Adeboye O $u Departments of Pathology and Urology, Emory University School of Medicine, Atlanta, GA, USA
700    1_
$a Rogala, Joanna $u Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Comperat, Eva $u Department of Pathology, University of Vienna, Vienna, Austria
700    1_
$a Gal, Viliam $u Department of Pathology, Alpha Medical Pathologia, Bratislava, Slovakia
700    1_
$a Dunatov, Ana $u Department of Pathology, University of Split, Croatia
700    1_
$a Pivovarcikova, Kristyna $u Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Michalova, Kvetoslava $u Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Vesela, Adriena Bartos $u Department of Urology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Slisarenko, Maryna $u Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Strakova, Andrea Peterikova $u Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Pitra, Tomas $u Department of Urology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Michal, Michal $u Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic
700    1_
$a Alaghehbandan, Reza $u Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada
700    1_
$a Hes, Ondrej $u Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic. Electronic address: hes@biopticka.cz
773    0_
$w MED00166541 $t Annals of diagnostic pathology $x 1532-8198 $g Roč. 60, č. - (2022), s. 151978
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35609473 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151137 $b ABA008
999    __
$a ok $b bmc $g 1891780 $s 1184554
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 60 $c - $d 151978 $e 20220520 $i 1532-8198 $m Annals of diagnostic pathology $n Ann. diagn. pathol. $x MED00166541
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Archiving options